Daniel D Shoemaker, Chief Scientific Officer, sold 25,000 shares of Fate Therapeutics (FATE) on Sep 14, 2020, for $907,540. Subsequent to the Form 4...
Fate Therapeutics (FATE) said Wednesday Edward Dulac has been appointed as its new finance chief. Dulac most recently served as vice president in Celgene's...
Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $37. (MT Newswires covers equity, commodity and economic...
Fate Therapeutics (FATE) on Wednesday reported a Q2 loss per diluted share of $0.35, narrower than the loss of $0.36 a year ago. Revenue increased to $5.5...
| Address | 3535 General Atomics Court San Diego, California 92121 |
| Phone | +1.858.875.1800 |
| Number of Employees | 104 |
| Recent SEC Filing | 09/16/2020 4 |
| President, Chief Executive Officer & Director | J. Scott Wolchko |
| Chief Financial Officer & Accounting Officer | Edward J. Dulac |
| Chief Scientific Officer | Daniel D. Shoemaker |
| Senior Vice President-Technical Operations | Wen Bo Wang |
| Price Open | $35.80 |
| Previous Close | $35.99 |
| 52 Week Range | $12.59 - 39.45 |
| Market Capitalization | $3.3 B |
| Shares Outstanding | 86.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/03/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.57 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.7 M |
| Net Profit Margin | -881.86% |
| Return on Equity | -38.64% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
